| Literature DB >> 27209488 |
Gunnar Damgård Nielsen1, Søren Thor Larsen2, Peder Wolkoff2.
Abstract
In 2010, the World Health Organization (WHO) established an indoor air quality guideline for short- and long-term exposures to formaldehyde (FA) of 0.1 mg/m3 (0.08 ppm) for all 30-min periods at lifelong exposure. This guideline was supported by studies from 2010 to 2013. Since 2013, new key studies have been published and key cancer cohorts have been updated, which we have evaluated and compared with the WHO guideline. FA is genotoxic, causing DNA adduct formation, and has a clastogenic effect; exposure-response relationships were nonlinear. Relevant genetic polymorphisms were not identified. Normal indoor air FA concentrations do not pass beyond the respiratory epithelium, and therefore FA's direct effects are limited to portal-of-entry effects. However, systemic effects have been observed in rats and mice, which may be due to secondary effects as airway inflammation and (sensory) irritation of eyes and the upper airways, which inter alia decreases respiratory ventilation. Both secondary effects are prevented at the guideline level. Nasopharyngeal cancer and leukaemia were observed inconsistently among studies; new updates of the US National Cancer Institute (NCI) cohort confirmed that the relative risk was not increased with mean FA exposures below 1 ppm and peak exposures below 4 ppm. Hodgkin's lymphoma, not observed in the other studies reviewed and not considered FA dependent, was increased in the NCI cohort at a mean concentration ≥0.6 mg/m3 and at peak exposures ≥2.5 mg/m3; both levels are above the WHO guideline. Overall, the credibility of the WHO guideline has not been challenged by new studies.Entities:
Keywords: Cancer; Formaldehyde; Indoor air guideline; Risk assessment; World Health Organization
Mesh:
Substances:
Year: 2016 PMID: 27209488 PMCID: PMC5225186 DOI: 10.1007/s00204-016-1733-8
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 5.153
Recent studies on cytogenetic effects in peripheral blood lymphocytes in formaldehyde (FA)-exposed employees
| Exposure | Number of participants; exposed ( | FA exposure in years, mean (range) or as indicated | Exposure in ppm: | Statistically significant association with FA exposure |
|---|---|---|---|---|
| Pathology laboratories (Costa et al. |
| 12 (SD 8.2) |
| CA: increased |
| Anatomy and Forensic medicine laboratories (Souza and Devi |
| 10.7 (1–30) |
| MN: increased |
| Pathology laboratory (Bouraoui et al. |
| 15.7 (SD 10.1) |
| MN: increased |
| Pathology laboratories (Costa et al. |
| 12.5 (1–30) |
| MN: increased |
| Histopathology laboratories (Ladeira et al. |
| ? |
| MN: increased |
| Pathological departments (Musak et al. |
| 14.7 (SD 10.4) |
| CA: increased |
| Plywood workers (Lin et al. | E (high): 38 ( | 2.52 (SD 2.0) for all in the high, low and int. groups |
| Comet: pos |
| E (low): 58 ( |
| Comet: pos | ||
| C (int): 82 ( |
| |||
|
| Effect across an 8 h workday |
| Comet: pos | |
| Medium density fiberboard plants (Aydin et al. |
| 7.3 (0.33–30) |
| Comet: significantly lower than in the controls |
CA chromosomal aberration, Comet comet assay and pos positive for genotoxicity, DPX DNA–protein cross-links, MN micronucleus, NBUD nuclear buds, NPB nucleoplasmic bridges, NS not significant, SCE sister chromatid exchange, TWA time-weighted average exposure, ? unknown concentration
Nasal epithelial squamous cell carcinomas (SCC) in combined groups of male and female rats from four long-term inhalation studiesa with formaldehyde (FA) exposures
| FA (ppm) | Rats with SCC/group size (% with SCC) |
|---|---|
| 0 | 0/453 (0) |
| 0.3 | 0/32 (0) |
| 0.7 | 0/90 (0) |
| 2 | 0/364 (0) (apparent NOAEC) |
| 6 | 3/325 (0.9) (apparent LOAEC) |
| 10 | 20/90 (22) |
| 14 | 103/232 (44) |
| 15 | 120/278 (43) |
aKerns et al. (1983), Sellakumar et al. (1985), Monticello et al. (1996) and Kamata et al. (1997). For review of details, see Nielsen and Wolkoff (2010) and Nielsen et al. (2013)
Cancer risks from formaldehyde exposures in three recently updated occupational cohorts
| Study | NCI cohort < 1966–2004 | UK cohort (1941–2012) | US garment worker cohort (1955–2008) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Exposure (ppm) | Median average intensity: 0.3 and range 0.01–4.3. Exposure to ≥ 1 occurred in 15 % and 24 % had peak exposures at ≥ 4 | Range <0.1 to >2 | Geometric mean: 0.15 and geometric standard deviation 1.90. Past exposures may have been about 4 ppm, see text | ||||||
| Risk estimatea | ICD-8 |
| SMR | ICD-9 |
| SMR | ICD-10 |
| SMR |
| All cancers | 140–209 | 3146b |
| 140–208 | 2241 |
| – | 1021 | 0.96 |
| Solid cancers | 140–199 | 2878b |
| – | – | – | – | – | – |
| Nose and nasal sinuses | 160 | 3b | 0.90 | – | 2 | 0.71 | C30–C31 | 0 | 0 |
| Pharynx | – | 17 | 1.20 | C09–C14 | 6 | 0.88 | |||
| Nasopharynx | 147 | 9b | 1.84 | – | 1 (E: 1.7) | 0.59 | C11 | 0 | 0 |
| Buccal cavity | 140–149 | 74b | 1.15 | – | 7 | 1.08 | C03–C08 | 6 | 1.42 |
| Larynx | 161 | 42b | 1.23 | – | 22 | 1.22 | C32 | 4 | 0.77 |
| Lung | 162 | 1130b |
| – | 813 |
| C33–C34c | 267 | 1.04 |
| Bone | 170 | 8b | 1.36 | – | – | – | – | ||
| Prostate | 185 | 261b | 1.07 | – | 147 |
| – | – | – |
| Pancreas | 157 | 111b |
| – | 91 | 1.04 | – | – | – |
| Breast | 174 | 28b |
| – | – | – | – | – | – |
| Hodgkin’s disease | 201 | 25 | 1.42 | – | – | – | C81 | 4 | 0.95 |
| Non-Hodgkin’s lymphoma | 200 | 94 | 0.85 | – | 53 | 1.06 | C46.3 | 44 | 1.13 |
| 202 | C82–C85 | ||||||||
| C88.0 | |||||||||
| C88.3 | |||||||||
| C91.4 | |||||||||
| C96 | |||||||||
| Multiple myelomas | 203 | 48 | 0.94 | – | 28 | 0.99 | C88.7 | 23 | 1.24 |
| C88.9 | |||||||||
| C90 | |||||||||
| Leukaemia | 204–207 | 116 | 1.02 | – | 54 | 1.02 | C91–C95 | 36 | 1.04 |
| Ex91.4 | |||||||||
| Myeloid leukaemia | 205 | 44 | 0.90 | – | 36 | 1.20 | C92 | 21 | 1.28 |
| Lymphatic leukaemia | 204 | 36 | 1.15 | – | – | – | C91–C91.9 | 6 | 0.71 |
| Stomach | – | – | – | – | 182 |
| – | – | – |
| Digestive system | 150–159 | 759b | 1.07 | – | 126 | 0.95d | – | – | – |
The US National Cancer Institute (NCI) cohort comprised 25,619 workers employed in 10 U.S. formaldehyde producing or using facilities. Workers were employed prior to January 1 1966 and were followed up through 31 December 2004 (Beane Freeman et al. 2009; Beane Freeman et al. 2013; number of death was 13,951 [11,346 among exposed and 2605 among unexposed (Beane Freeman et al. 2013)]. Exposures were from Beane Freeman et al. (2009). A British (UK) cohort from six British factories, comprising 14,008 men followed up from 1941 through December 2012; number of death were 7378 (Coggon et al. 2014). The US National Institute for Occupational Safety and Health had established a cohort with 11,034 employees in three garment facilities (US garment worker cohort); number of death was 3915. The study was updated through 31 December 2008 (Meyers et al. 2013)
aStandardized mortality ratio (SMR) was obtained by comparison with the national death rates. The number of observed death due to the type cancer among exposed workers is indicated by “O” and the expected number of cases by “E” where relevant for calculation of SMR. When a 95 % confidence interval does not include 1.00, this is indicated by * and bold. Excluded is indicated with Ex. The International Classification of Diseases is indicated by 8th revision (ICD-8), 9th revision (ICD-9) and the 10th (ICD-10). Not given is indicated by “–”
bBeane Freeman et al. (2013)
cComprising the trachea, bronchus and lung
dLarge intestine
Exposure-dependent effect of FA on development of nasopharyngeal cancer in the three formaldehyde exposure metrics in the US National Cancer Institute Cancer Cohort; the reference group was the lowest exposure category in each exposure metric (Beane Freeman et al. 2013)
| Peak exposure | Average intensity | Cumulative exposure | |||
|---|---|---|---|---|---|
| ppm | RR (95 % CI) ( | ppm | RR (95 % CI) ( | ppm × year | RR (95 % CI) ( |
| 0 | 4.4 (0.3–54) (2) | 0 | 6.8 (0.5–84) (2) | 0 | 1.9 (0.3–12) (2) |
|
| RR = 1 (1) | 0.1–0.4 | RR = 1 (1) | >0 to <1.5 | RR = 1 (4) |
| 2.0 to <4.0 | NAa (0) | 0.5–0.9 | 2.4 (0.15–39) (1) | 1.5 to <5.5 | 0.86 (0.1–7.7) (1) |
| ≥ 4.0 | 7.7 (0.9–62) (7) | ≥1 |
| ≥5.5 | 2.9 (0.6–13) (3) |
|
|
|
| |||
|
|
|
| |||
The cohort comprises 25,619 workers. Number of NPC cases is indicated by N, and a significant increase is indicated in bold
aNot applicable (NA)
Relative risk (RR) of lymphohaematopoietic malignancies in the recent update of the National Cancer Institute Cohort
| Average intensity | Peak exposure | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease (ppm) | All | NHL | HL | MM | ML | Disease (ppm) | All | NHL | HL | MM | ML |
| 0 | 0.99a | 1.08 | 0.53 (0.11–2.66) |
| 0.70 (0.23–2.16) | 0 | 1.07 (0.70–1.62) | 1.06 | 0.67 (0.12–3.60) |
| 0.82 (0.25–2.67) |
| >0 to <0.5 | 1.0 Ref | 1.0 Ref | 1.0 Ref | 1.00 Ref | 1.0 Ref | >0 to <2.0 | 1.0 Ref | 1.0 Ref | 1.0 Ref | 1.0 Ref | 1.0 Ref |
| 0.5 to <1.0 | 1.29 | 1.20 |
| 1.40 | 1.21 (0.56–2.62) | 2.0 to <4.0 | 1.17 (0.86–1.59) | 1.08 |
| 1.65 (0.76–3.61) | 1.30 (0.58–2.92) |
| ≥1.0 | 1.07 | 0.71 | 2.48 (0.84–7.32) | 1.49 | 1.61 (0.76–3.39) | ≥4.0 |
| 0.91 |
|
| 1.78 (0.87–3.64) |
|
| >0.5 | 0.4 |
| >0.50 | 0.40 |
| 0.04 | >0.50 |
| 0.50 | 0.07 |
|
| >0.5 | >0.5 |
| >0.50 | 0.43 |
| 0.02 | >0.50 |
| 0.08 | 0.13 |
Beane Freeman et al. Mortality from lymphohaematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort. J Natl Cancer Inst 2009; 101: 751–761
All Lymphohaematopoietic malignancies (ICD-8: 200–209), NHL non-Hodgkin’s lymphoma (ICD-8: 200 & 202), HL Hodgkin’s lymphoma (ICD-8: 201), ML myeloid leukaemia (ICD-8:205), MM multiple myeloma (ICD-8: 203). Ref referent group. P(0 + FA) is the P of trend including all four groups and P(FA) is the P of trend exclusively in the FA groups
aRelative risk [RR (95 % CI)]. The 95 % confidence limits have only been added, where relevant for risk assessment. Significant values are given in bold